Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;134(21):e186744.
doi: 10.1172/JCI186744.

Hidradenitis suppurativa: key insights into treatment success and failure

Kelsey R van Straalen  1 , Vincent Piguet  2   3 , Johann E Gudjonsson  4   5   6
Affiliations

Hidradenitis suppurativa: key insights into treatment success and failure

Kelsey R van Straalen et al. J Clin Invest. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: KRVS has received honoraria or fees for consulting and/or speaking from Novartis, UCB, and Boehringer-Ingelheim. VP has received honoraria or fees for consulting and/or speaking for AbbVie, Almirall, Celgene, Janssen, Novartis, and Pfizer. JEG has received research support from AbbVie, Janssen, Almirall, Prometheus Biosciences/Merck, BMS/Celgene, Boehringer Ingelheim, Galderma, and Eli Lilly, and has served as advisor to Sanofi, Eli Lilly, Galderma, BMS, and Boehringer Ingelheim.

Figures

Figure 1
Figure 1. Outline of discussed current and future therapeutics within an active HS lesion.
Outline of an active HS lesion with active sinus tracts demonstrating the targets of current and upcoming therapeutics. Colors used for the treatments depicted: red, promising trial results; orange, trails that failed to meet their primary endpoint or demonstrated low response; gray, no clinical trials or published data yet.
See this image and copyright information in PMC

References

    1. Ingram JR, et al. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917–924. doi: 10.1111/bjd.16101. - DOI - PubMed
    1. van Straalen KR, et al. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149(4):1150–1161. doi: 10.1016/j.jaci.2022.02.003. - DOI - PubMed
    1. Gudjonsson JE, et al. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight. 2020;5(19):e139930. doi: 10.1172/jci.insight.139930. - DOI - PMC - PubMed
    1. Kimball AB, et al. Efficacy and safety of the oral Bruton’s tyrosine kinase inhibitor, remibrutinib, in patients with moderate to severe hidradenitis suppurativa in a randomized, phase 2, double-blind, placebo-controlled platform study. Paper presented at the 2024 American Academy of Dermatology Meeting; March 8–12, 2024; San Diego, California, USA. https://am2024.aad.org/sessions/16895 Accessed September 18, 2024.
    1. Jepsen R, et al. A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa. J Am Acad Dermatol. 2023;89(4):694–702. doi: 10.1016/j.jaad.2023.05.076. - DOI - PubMed